A digital microfluidic device integrated with electrochemical sensor and 3D matrix for detecting soluble PD-L1.

ABSTRACT: PD1/PD-L1 checkpoint inhibitors are at the forefront of cancer immunotherapies. However, the overall response rate remains only 10-30%. Even among initial responders, drug resistance often occurs, which can lead to prolonged use of a futile therapy in the race with the fatal disease. It would be ideal to closely monitor key indicators of patients' immune responsiveness, such as circulating PD-L1 levels. Traditional PD-L1 detection methods, such as ELISA, are limited in sensitivity and rely on core lab facilities, preventing their use for the regular monitoring. Electrochemical sensors exist as an attractive candidate for point-of-care tool, yet, streamlining multiple processes in a single platform remains a challenge. To overcome this challenge, this work integrated electrochemical sensor

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC11290324 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature